Skip to main content
Premium Trial:

Request an Annual Quote

Fluidigm

Premium

South San Francisco-based Fluidigm has introduced its Topaz Growth Chip for protein crystal formation. The chip is the first in a line of microfluidic devices that Fluidigm is planning to release for the generation of large, diffraction-quality protein crystals, according to the company. The company already released a set of crystallization screening chips based on its microfluidics technology back in March 2003, but the crystals produced from such screens often do not fill the necessary size and quality requirements for X-ray diffraction. The growth chip, however, does fill these requirements, according to the company. “The introduction of Topaz diffraction chips represents a significant step toward Fluidigm’s goal of commercializing a system the redefines protein crystallization as a routine, reliable process,” Gajus Worthington, Fluidigm’s CEO, said in the statement. Fluidigm has been collaborating since September 2003 with GlaxoSmithKline to develop the Topaz platform.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.